Key result
This paper is a protocol for a systematic review and meta-analysis evaluating the benefits and harms of prothrombin complex concentrate in critically bleeding patients treated with oral anticoagulants, and thus contains no clinical results.
Why the study?
Does prothrombin complex concentrate improve outcomes in critically bleeding patients treated with oral anticoagulants?
Systematic Review
Does prothrombin complex concentrate improve outcomes in critically bleeding patients treated with oral anticoagulants?
This protocol outlines a planned systematic review and meta-analysis to evaluate the efficacy and safety of prothrombin complex concentrate for reversing oral anticoagulant-induced coagulopathy in critically bleeding patients.
Answers are grounded in this paper and cite their sources.
No immediate practice change from this protocol; upcoming meta-analysis leaves optimal PCC reversal open pending synthesis.
Acute critical bleeding is one of the most feared complications during treatment with oral anticoagulating agents. As more patients undergo treatment with anticoagulating agents, critically bleeding episodes in patients with vitamin K antagonists, thrombin inhibitor, or factor Xa inhibitor-inducted coagulopathy will be encountered frequently by physicians. Hence, an effective treatment capable of reversing the iatrogenic coagulopathy in the acute setting is needed. In randomised clinical trials and observational studies, prothrombin complex concentrate has been reported to be superior to other acute interventions, and many guidelines recommend prothrombin complex concentrate in treatment of critically bleeding patients. The aim of this systematic review is to synthesise the evidence of the effects of prothrombin complex concentrate compared with placebo, no intervention, or other treatment options in critically bleeding patients treated with oral anticoagulants. A comprehensive search for relevant published literature will be undertaken in Cochrane Central Register of Controlled Trials, MEDLINE, Embase, WHO International Clinical Trials Registry Platform, Science Citation Index, regulatory databases, and trial registers. We will include randomised clinical trials comparing prothrombin complex concentrate versus placebo, no intervention, or other interventions in critically bleeding patients with oral anticoagulant-induced coagulopathy. Data extraction and risk of bias assessment will be handled by two independent review authors. Meta-analysis will be performed as recommended by Cochrane Handbook for Systematic Reviews of Interventions, bias will be assessed with domains, and trial sequential analysis will be conducted to control random errors. Certainty will be assessed by GRADE. As critical bleeding in patients treated with oral anticoagulants is an increasing problem, an up-to-date systematic review evaluating the benefits and harms of prothrombin complex concentrate is urgently needed. It is the hope that this review will be able to guide best practice in treatment and clinical research of these critically bleeding patients.
No takes yet. Share an insight, caveat, or question.
Ovesen et al. (2018) conducted a systematic review in Critical bleeding associated with oral anticoagulant administration. Prothrombin complex concentrate vs. Placebo, no intervention, fresh frozen plasma, vitamin K, or other interventions was evaluated on All-cause mortality, health-related quality of life, and serious adverse events. This paper is a protocol for a systematic review and meta-analysis evaluating the benefits and harms of prothrombin complex concentrate in critically bleeding patients treated with oral anticoagulants, and thus contains no clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: